Targets › IL1RN
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Nov 2026.
Anti-inflammatory antagonist of interleukin-1 family of pro-inflammatory cytokines such as interleukin-1beta/IL1B and interleukin-1alpha/IL1A. Protects from immune dysregulation and uncontrolled systemic inflammation triggered by IL1 for a range of innate stimulatory agents such as pathogens. (UniProt, P18510)
Open in Phaseline: the race on IL1RN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pacira Pharmaceuticals | FX201 (humantakinogene hadenovec) interleukin-1 receptor antagonist (IL-1Ra) gene therapy | IL1RN | Phase 1 | Osteoarthritis, Knee | Nov 2026 |
Osteoarthritis, Knee (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.